



January 9, 2017

## PerkinElmer to Acquire Tulip Diagnostics Private Limited in India

- | **Extends PerkinElmer's Infectious Disease Screening Capabilities**
- | **Supports Company's Growth in Emerging Market Diagnostics**

WALTHAM, Mass.--(BUSINESS WIRE)-- [PerkinElmer, Inc.](#) (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it has entered into a definitive agreement to acquire [Tulip Diagnostics Private Ltd.](#) Based in Goa, India, Tulip is one of the country's largest domestic providers of in-vitro diagnostic reagents, kits and instruments to an expansive customer base of diagnostic labs and government and private healthcare facilities. Tulip's solutions include products for the prevention, screening and diagnosis of infectious diseases such as malaria, HIV and hepatitis.

"As we continue to build out our Diagnostics business on a global scale, this acquisition further positions PerkinElmer for long-term growth in emerging market diagnostics, an attractive end market and key area of focus for us," said Prahlad Singh, Senior Vice President and President, Diagnostics, PerkinElmer. "We are committed to expanding our infectious disease screening menu and capabilities, and Tulip's product portfolio, channel access, and broad footprint provide the key enablers to help accelerate our growth in this important market."

PerkinElmer offers a global diagnostics portfolio focused on: reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings.

The transaction is currently anticipated to close in the first quarter of 2017.

### **About PerkinElmer, Inc.**

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. The Company reported revenue of approximately \$2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE or at [www.perkinelmer.com](http://www.perkinelmer.com).

### *Factors Affecting Future Performance*

*This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) the approval of the Brexit Referendum in the United Kingdom; (21) our ability to realize the full value*

*of our intangible assets; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.*

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170109006287/en/>

PerkinElmer, Inc.

Investor Relations:

Tommy J. Thomas, 781-663-5889

[tommy.thomas@perkinelmer.com](mailto:tommy.thomas@perkinelmer.com)

or

Media:

Brian Willinsky, 781-663-5728

[brian.willinsky@perkinelmer.com](mailto:brian.willinsky@perkinelmer.com)

Source: PerkinElmer, Inc.

News Provided by Acquire Media